289 related articles for article (PubMed ID: 21763448)
1. Regulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by non-steroidal anti-inflammatory drugs (NSAIDs).
Tai HH; Chi X; Tong M
Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):37-40. PubMed ID: 21763448
[TBL] [Abstract][Full Text] [Related]
2. 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells.
Chi X; Freeman BM; Tong M; Zhao Y; Tai HH
Arch Biochem Biophys; 2009 Jul; 487(2):139-45. PubMed ID: 19501039
[TBL] [Abstract][Full Text] [Related]
3. Sulindac reversal of 15-PGDH-mediated resistance to colon tumor chemoprevention with NSAIDs.
Fink SP; Dawson DM; Zhang Y; Kresak A; Lawrence EG; Yang P; Chen Y; Barnholtz-Sloan JS; Willis JE; Kopelovich L; Markowitz SD
Carcinogenesis; 2015 Feb; 36(2):291-8. PubMed ID: 25503930
[TBL] [Abstract][Full Text] [Related]
4. 15-Hydroxyprostaglandin-dehydrogenase is involved in anti-proliferative effect of non-steroidal anti-inflammatory drugs COX-1 inhibitors on a human medullary thyroid carcinoma cell line.
Quidville V; Segond N; Lausson S; Frenkian M; Cohen R; Jullienne A
Prostaglandins Other Lipid Mediat; 2006 Oct; 81(1-2):14-30. PubMed ID: 16997128
[TBL] [Abstract][Full Text] [Related]
5. Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase.
Wakimoto N; Wolf I; Yin D; O'Kelly J; Akagi T; Abramovitz L; Black KL; Tai HH; Koeffler HP
Cancer Res; 2008 Sep; 68(17):6978-86. PubMed ID: 18757412
[TBL] [Abstract][Full Text] [Related]
6. Indomethacin, a cox inhibitor, enhances 15-PGDH and decreases human tumoral C cells proliferation.
Frenkian M; Segond N; Pidoux E; Cohen R; Jullienne A
Prostaglandins Other Lipid Mediat; 2001 May; 65(1):11-20. PubMed ID: 11352223
[TBL] [Abstract][Full Text] [Related]
7. Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1.
Moon Y; Bottone FG; McEntee MF; Eling TE
Mol Cancer Ther; 2005 Oct; 4(10):1551-8. PubMed ID: 16227405
[TBL] [Abstract][Full Text] [Related]
8. A potential anti-tumor effect of leukotriene C4 through the induction of 15-hydroxyprostaglandin dehydrogenase expression in colon cancer cells.
Mehdawi LM; Satapathy SR; Gustafsson A; Lundholm K; Alvarado-Kristensson M; Sjölander A
Oncotarget; 2017 May; 8(21):35033-35047. PubMed ID: 28402256
[TBL] [Abstract][Full Text] [Related]
9. The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells.
Ishibashi M; Bottone FG; Taniura S; Kamitani H; Watanabe T; Eling TE
Exp Cell Res; 2005 Jan; 302(2):244-52. PubMed ID: 15561105
[TBL] [Abstract][Full Text] [Related]
10. Identification of dual cyclooxygenase-eicosanoid oxidoreductase inhibitors: NSAIDs that inhibit PG-LX reductase/LTB(4) dehydrogenase.
Clish CB; Sun YP; Serhan CN
Biochem Biophys Res Commun; 2001 Nov; 288(4):868-74. PubMed ID: 11688989
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin catabolic enzymes as tumor suppressors.
Tai HH
Cancer Metastasis Rev; 2011 Dec; 30(3-4):409-17. PubMed ID: 22020925
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) by cyclooxygenase inhibitors and chemopreventive agents.
Cho H; Tai HH
Prostaglandins Leukot Essent Fatty Acids; 2002 Dec; 67(6):461-5. PubMed ID: 12468268
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-4 up-regulates 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in human lung cancer cells.
Chi X; Tai HH
Exp Cell Res; 2010 Aug; 316(14):2251-9. PubMed ID: 20632471
[TBL] [Abstract][Full Text] [Related]
15. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.
Yan M; Rerko RM; Platzer P; Dawson D; Willis J; Tong M; Lawrence E; Lutterbaugh J; Lu S; Willson JK; Luo G; Hensold J; Tai HH; Wilson K; Markowitz SD
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17468-73. PubMed ID: 15574495
[TBL] [Abstract][Full Text] [Related]
16. Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells.
Tong M; Ding Y; Tai HH
Carcinogenesis; 2006 Nov; 27(11):2170-9. PubMed ID: 16632868
[TBL] [Abstract][Full Text] [Related]
17. Non-canonical WNT5A signaling up-regulates the expression of the tumor suppressor 15-PGDH and induces differentiation of colon cancer cells.
Mehdawi LM; Prasad CP; Ehrnström R; Andersson T; Sjölander A
Mol Oncol; 2016 Nov; 10(9):1415-1429. PubMed ID: 27522468
[TBL] [Abstract][Full Text] [Related]
18. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer.
Thiel A; Ganesan A; Mrena J; Junnila S; Nykänen A; Hemmes A; Tai HH; Monni O; Kokkola A; Haglund C; Petrova TV; Ristimäki A
Clin Cancer Res; 2009 Jul; 15(14):4572-80. PubMed ID: 19584167
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
Richter M; Weiss M; Weinberger I; Fürstenberger G; Marian B
Carcinogenesis; 2001 Jan; 22(1):17-25. PubMed ID: 11159736
[TBL] [Abstract][Full Text] [Related]
20. Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.
Castro-Sánchez L; Agra N; Llorente Izquierdo C; Motiño O; Casado M; Boscá L; Martín-Sanz P
Int J Biochem Cell Biol; 2013 Nov; 45(11):2501-11. PubMed ID: 23954207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
